| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 102,298 | 97,373 | ||
| Short-term investments | 221,346 | 305,967 | ||
| Research and development incentives receivable | 1,806 | 1,843 | ||
| Prepaid expenses and other current assets | 8,299 | 8,188 | ||
| Total current assets | 333,749 | 413,371 | ||
| Property, plant and equipment, net | 14,711 | 14,679 | ||
| Research and development incentives receivable, non-current | 799 | 431 | ||
| Restricted cash | 1,705 | 1,707 | ||
| Other non-current assets | 1,200 | 1,200 | ||
| Right-of-use asset - operating leases | 3,692 | 3,918 | ||
| Right-of-use asset - financing leases | 33,594 | 34,201 | ||
| Total assets | 389,450 | 469,507 | ||
| Accounts payable | 6,404 | 15,483 | ||
| Accrued expenses and other current liabilities | 42,445 | 40,041 | ||
| Operating lease liabilities, current | 1,210 | 1,220 | ||
| Financing lease liabilities, current | 2,841 | 2,820 | ||
| Total current liabilities | 52,900 | 59,564 | ||
| Operating lease liabilities, non-current | 2,723 | 2,953 | ||
| Financing lease liabilities, non-current | 22,344 | 22,542 | ||
| Long term debt, net of discount | 47,206 | 46,792 | ||
| Other liabilities, non-current | 941 | 941 | ||
| Total liabilities | 126,114 | 132,792 | ||
| Common stock, 0.001 par value 150,000,000 shares authorized as of september 30, 2025 and march 31, 2025 78,403,255 and 77,085,024 shares issued and outstanding as of september 30, 2025 and march 31, 2025, respectively | 78 | 78 | ||
| Additional paid-in capital | 1,376,507 | 1,367,668 | ||
| Accumulated deficit | -1,118,372 | -1,035,272 | ||
| Accumulated other comprehensive income | 5,123 | 4,241 | ||
| Total stockholders' equity | 263,336 | 336,715 | ||
| Total liabilities and stockholders' equity | 389,450 | 469,507 | ||
Replimune Group, Inc. (REPL)
Replimune Group, Inc. (REPL)